Phase 1 dose escalation study of rigosertib by 2-, 4-, or...

Phase 1 dose escalation study of rigosertib by 2-, 4-, or 8-hour infusion twice-weekly in patients with advanced cancer

Raghunadharao, D, Wilhelm, FE, Acharya, M, Advani, SH, Achrekar, SD, Doval, DC
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
51
Year:
2014
Language:
english
Journal:
Indian Journal of Cancer
DOI:
10.4103/0019-509X.134617
File:
PDF, 513 KB
english, 2014
Conversion to is in progress
Conversion to is failed